Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
54.3K
-
Shares change
-
-17.4K
-
Total reported value, excl. options
-
$488K
-
Value change
-
-$136K
-
Number of sells
-
-2
-
Price
-
$8.99
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q4 2023
2 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q4 2023.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.3K shares
of 131M outstanding shares and own 0.04% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (9.54M shares), BlackRock Inc. (8.92M shares), NEA Management Company, LLC (3.97M shares), STATE STREET CORP (2.7M shares), Nuveen Asset Management, LLC (2.35M shares), GOLDMAN SACHS GROUP INC (2.05M shares), GEODE CAPITAL MANAGEMENT, LLC (1.57M shares), VANGUARD GROUP INC (1.51M shares), MORGAN STANLEY (1.45M shares), and CITIGROUP INC (1.42M shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.